Overview

Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma

Status:
Completed

Trial end date:
2012-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of single doses of three different dry powder inhalation formulations of AZD3199 administered via Single Inhalation Device (SID) compared to AZD3199 administered via Turbuhaler™ Inhaler and compared to placebo in patients with persistent asthma.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

AZD-3199